Beta 2-microglobulin (, 2-m) forms the light chain moiety of HL-A (loci A, B, C). Cell membrane turnover is the principal source of free #2-m in blood plasma and body fluids (Cresswell et al., 1974) . The serum level is raised in a variety of malignancies and appears to be a reflection of tumour load in many patients with lymphomas and myelomatosis, (Amlot et al., 1978; Child et al., 1980; Cooper et al., 1981; Bataille et al., 1981; Norfolk et al., 1980) , though its exact cellular origin is as yet uncertain.
It has been suggested that serum ,B2-m may be of value as a prognostic indicator in myelomatosis (Norfolk et al., 1980) . Sixty-four patients with this disease presenting to two centres were therefore investigated in order to compare the prognostic information provided by this single protein measurement with that obtained from existing staging systems, other clinical features and "standard" laboratory measurements. To confirm the results relating survival to serum #2-m an additional group of 65 patients from a third centre were investigated. Durie and Salmon (1975) ; the distribution within the 2 main sub-groups is shown in Table I . The Phadebas /2-Micro test (Pharmacia, Uppsala, Sweden) was used to measure serum ,B2-m, which rises slightly with age but in normal people it rarely exceeds 3 mgl-1. This level has been taken as the upper limit of normal appropriate for the age of patients studied. Measurements were made before treatment was started and at 3, 6 and 12 months from diagnosis.
All serum #2-m measurements were carried out in one laboratory (Unit for Cancer Research, University of Leeds). The details of treatment are not relevant but most patients were treated with various combinations of melphalan, cyclophosphamide and prednisolone.
Statistical methods: A multivariate regression model (Cox, 1972) was Durie & Salmon (1975). used to assess how different factors related to patient survival. This model can be used to indicate the additional prognostic value of a given factor after allowance has been made for others. Survival curves using this model were calculated using the methods suggested by Breslow (1974) . The calculations needed to obtain confidence bands were those given by Tsiatis (1981) and O'Quigley (1982) . The log rank methods of Peto et al. (1977) are appropriate when dealing with discrete prognostic terms; in the present study, however, continuous measurements of /32-m were used because it was felt that information would be lost by using an arbitrary cut-off level as in an earlier study (Norfolk et al., 1980 The levels of serum ,B2-m at first presentation and the median survival of subsets, designated by the initial ,B2-m are shown in Table II . There was a close similarity in the pattern of results for the 2 patient groups. The remainder of the analyses refer to Group A patients. The probability of survival given the initial value of serum ,B2-m as calculated from Cox's regression model is shown in Table III . The figure shows the estimated survival of patients with "high" (12.0mg1-F) and "low" (2.5mgl1) #2-m levels at diagnosis with the 95% confidence bands.
Comparison between serum /32-m and standard data:
The relationship between the pre-treatment serum /B2-m and survival was compared with standard clinical and laboratory data obtained at presentation. The significance levels of these associations are presented in (12.Omgl-') and "low" (2.5mgl-') serum ,B2-m levels at diagnosis, with 95% confidence bands.
model after accounting for the standard data is shown in Table V . Haemoglobin and blood urea were both, as expected, indicators of prognosis but they were not individually or together as powerful as serum /32-m; the addition of serum /32-m to the model gave a significant result even after haemoglobin and blood urea had been taken into account. Similarly, clinical stage and survival showed a relationship which was significantly enhanced by the addition of serum #32-m (Table V) . By including the serial measurement of serum /32-m made at 3, 6 and 12 months after diagnosis as well as the initial measurement, a highly significant result was obtained (P <0.001) but only slightly more powerful than that using the initial 
Discussion
The staging of myelomatosis has, in recent years, been dominated by the system of Durie and Salmon (1975) which has been shown to give a good correlation between stage and survival (Woodruff et al., 1979) but which has been criticised because it allocates a high proportion of cases to Stage III (1975) . (Parker & Malpas, 1979) . The Medical Research Council group found that the blood urea and the haemoglobin level were the most significant parameters in assessing the prognosis of myeloma patients and together with performance status they form the basis of the system of staging which they adopted. (Medical Research Council, 1980) . The results of the present study have shown that serum 42-m measured at presentation has a strong association with survival, the data for 2 comparable groups of patients being very similar. The additional analyses revealed that the serum /2-m was a better guide to prognosis than the other "standard" clinical and laboratory data, whether derived from the combination of haemoglobin level and blood urea or stage based on the system of Durie & Salmon (1975) .
The haemoglobin level is likely to be related to marrow involvement and therefore, tumour load, whilst blood urea reflects the renal effects of myelomatosis, probably light chain excretion. The level of P2-m in serum, reflecting myeloma cell mass but also rising as the glomerular filtration rate falls, represents the net effect of tumour mass together with a contribution from reduced filtration in patients with impaired renal function. The serum 32-m continues to give powerful prognostic information after the institution of treatment as demonstrated by the findings at one year. This reinforces earlier observations that the prognosis for patients whose serum /32-m levels fall and stabilise at normal or near normal levels after treatment is better than for patients with persistently high or rising levels (Norfolk et al., 1980) .
It is concluded that the serum ,B2-m at diagnosis carries more prognostic information than any of the commonly used indicators in myelomatosis and should, therefore, have a valuable role in the investigation of patients with this disease and their stratification for clinical trial purposes. The use of a single simple measurement has obvious attractions.
